Genetic Technologies Limited (GENE) Return on Investment ROI from the fourth quarter of 2024 to fourth quarter of 2019 and for the year 2024, average high and low, overall ranking from Jun 30 2024 to Jun 30 2019 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Genetic Technologies Limited  (GENE)


Genetic Technologies Limited's ROI from its fourth quarter of 2024 to the fourth quarter of 2019 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Genetic Technologies Limited's ROI in the fourth quarter of 2024?
Genetic Technologies Limited recorded a cumulative net loss of $-12 million during 12 months ending in the fourth quarter of 2024, resulting in a negative return on investment (ROI) of -800.41%.

Within the Healthcare sector 926 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2024 from to 4753.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2024)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Jun 30 2019)
IV. Quarter
Y / Y Investment Change TTM -87.21 % -79.67 % -71.96 % -49.17 % 18.87 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 1 1 1 2 8
Return On Investment (TTM) -800.41 % -207.81 % -136.44 % -87.98 % -54.73 %
GENE's Overall Ranking # 4753 # # # #
Seq. Investment Change TTM -51.44 % -34.35 % -35.52 % -37.79 % -22.8 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -12 -6 -6 -6 -6

GENE Company Profile >> Back to GENE Roi Comparisons >> See Annual GENE Return On Investment



Return On Investment GENE's Ranking
Within: No.
Industry # 139
Sector # 927
Overall # 4753

Return On Investment Statistics
High Average Low
-32.7 %
-195.94 %
-596.7 %
(Jun 30 2021)   (Jun 30 2024)



  News about Genetic Technologies Limited Return on Investment ROI

Genetic Technologies Limited: Solid Gain in Shares Amidst Expansion into New Global Markets

January 31, 2024



Genetic Technologies Limited (NASDAQ: GENE) is making significant strides in the field of personalized predictive genomics, transforming the healthcare industry with its groundbreaking approach to early disease detection and personalized wellness. With the release of its business update for the quarter ending 31 December 2023, the company has reported a stellar 9.38% gain in shares over the past five trading days. This positive development comes as Genetic Technologies Limited expands its reach into new global markets, aiming to reshape healthcare practices on a global scale.
Expanding into New Global Markets:
Genetic Technologies Limited s latest business update outlines the successful expansion of the company into new global markets. By broadening its geographic footprint, the company aims to bring its innovative personalized genomics solutions to a wider audience, enabling individuals worldwide to proactively monitor and manage their health. This expansion marks a significant milestone for Genetic Technologies Limited and underscores its commitment to revolutionizing healthcare on a global level.

Genetic Technologies Achieves Compliance with Nasdaq Minimum Bid Price Requirement, Rebounding from Previous Challenges

January 5, 2024


Melbourne, Australia - In an exciting development, Genetic Technologies Limited (NASDAQ: GENE) announces that it has regained compliance with the minimum bid price requirement prescribed by the Nasdaq Stock Market, LLC (Nasdaq). The leading global genomics-based test provider, specializing in health, wellness, and serious diseases, received formal notice from Nasdaq confirming its successful compliance with the Nasdaq Listing Rule 5550(a)(2).
Earlier, on July 17, 2023, Genetic Technologies had received written notice from Nasdaq indicating its failure to meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market. However, the company has effectively addressed this concern and reestablished compliance, boosting investor confidence.





Financial Statements
Genetic Technologies Limited's IV. Quarter Investments $ 1 Millions GENE's Balance sheet
Genetic Technologies Limited's IV. Quarter Income $ -12 Millions Quarterly GENE's Income Statement
GENE's Income by Division See GENE's Income by Division


GENE Annual Return On Investment (Jun 30 2024)
2024		 (Jun 30 2023)
2023		 (Jun 30 2022)
2022		 (Jun 30 2021)
2021		 (Jun 30 2020)
2020
Total Investments in Millions 1 8 12 22 14
Y / Y Investment Growth -82.38 % -34.43 % -45.6 % 52.3 % 603.43 %
Net Income in Millions -8 -8 -5 -5 -4
Y / Y Net Income Growth - - - - -
Annual Return On Investment -581.17 % -102.84 % -44.11 % -24.52 % -29.83 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
GENE's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for GENE's Competitors
Subscribers only: Roi for Genetic Technologies Limited's Suppliers
Subscribers only: Return On Investment for GENE's Customers

Other Ratios
GENE's Roa GENE's Inventory Turnover Ratio GENE's Growth Rates GENE's Dividend Statistics
GENE's Profitability Ratios GENE's Asset Turnover Ratio GENE's Dividend Growth
GENE's Roe GENE's Valuation Ratios GENE's Financial Strength Ratios GENE's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2024, within Healthcare Sector ROI

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.